The U.S. Food and Drug Administration (FDA) recently approved Ixempra to be used in patients with metastatic breast cancer who have not responded to certain other cancer drugs.
The drug was approved to be used in combination with capecitabine, another cancer drug. It is to be used for patients who do not benefit from two other chemotherapy treatments???an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel)???any longer. Ixempra was also approved for use in patients who no longer benefit from an anthracycline, a taxane and capecitabine, without being combined with capecitabine.
“This approval is important because it provides certain patients with a new chemotherapy option in instances where other drugs have failed,” said Douglas C. Throckmorton, M.D., deputy director of the FDA’s Center for Drug Evaluation and Research. “FDA is working every day to support the development of safe and effective new therapies that benefit patients in need.”